Pharmaceutical
Learn about the latest developments in the pharmaceutical cannabis industry with Business of Cannabis. Discover new drugs, research, and more.
Pharmaceutical · page 4
- Pharmaceutical
European Cannabis Stocks Review: Akanda Announces ‘First Significant Revenue Above Initial Projections’
Akanda Akanda has enjoyed a sharp recovery in its share price this week, seeing its value return to levels not seen since October.
- Pharmaceutical
Virginia House panel kills GOP-led push to legalize retail cannabis sales
VIRGINIA CANNABIS Virginia House panel kills GOP-led push to legalize retail cannabis sales Benzinga reports that Virginia lawmakers struck down a push to legalize and set a framework for retail sales of recreational cannabis on Tuesday.
- Pharmaceutical
Jazz Pharmaceuticals Receives NICE Recommendation For The Reimbursement Of Epidyolex (Cannabidiol) For The Treatment Of Seizures Associated With Tuberous Sclerosis Complex In England
PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals (“GW”; now part of Jazz Pharmaceuticals plc), a world leader in discovering, developing and delivering regulatory approved cannabinoid-based medicines, has been recommended for reimbursement by National Institute for Health and Care Excellence (NICE) for adjunctive therapy…
- Pharmaceutical
Three firms steer e-cig and cannabis firm’s $42m IPO filing
INSPIRE TECHNOLOGY Three firms steer e-cig and cannabis firm’s $42m IPO filing Law 360 reports that the e-cigarette and cannabis vaping product brand Ispire Technology plans to raise up to USD$42 million by offering six million shares at a price range of $6 to $8 each.
- Pharmaceutical
European Cannabis Stocks Review: OCT Shares Fall As Co-Founder Divests, Cannabis Poland Secures Funding, & Akanda’s Legal Battle Continues
Oxford Cannabinoid Technologies THE pharmaceutical cannabis company has seen its shares drop around 25% this week, following weeks of the first significant growth in its share price for months.
- CBD Market
The Nasdaq stock exchange warns Organigram Holdings about their share price
SHARE-PRICE WARNING The Nasdaq stock exchange warns Organigram Holdings about their share price The Nasdaq stock exchange has warned Organigram Holdings about its share price, which has fallen below Nasdaq’s $1 minimum bid price requirement for 30 days in a row, reports MJ Biz Daily.
- Pharmaceutical
UK’s Medical Cannabis Industry Enjoys Strong Start To 2023
LAST week a flurry of positive announcements from across the UK’s medical cannabis industry were unveiled in signs the industry is wasting no time in shaking off the stagnation of 2022.
- CBD Market
Weed legalization supported by majority of U.S. voters
MAJORITY RULES Weed legalization supported by majority of U.S. voters According to a survey conducted by polling firm Data for Progress, most voters support legalising recreational cannabis at the federal level, writes Morgan Paxhia for Kiplinger.
- Pharmaceutical
European Cannabis Stocks Review: Celadon Shares Jump After Regulatory Win, IM Cannabis Closes Private Placement, & More From SEED
IM Cannabis IM Cannabis saw its stock price jump by nearly 10% this week after it announced the receipt of US$500k in funding in a private placement led by two company insiders.
- Pharmaceutical
First cannabis retail store owned by a victim of the war on drugs to open in New York
SOCIAL EQUITY APPLICANT First cannabis retail store owned by a victim of the war on drugs to open in New York The new dispensary, which like the first currently operating one will also be located in Manhattan, is scheduled to open for a soft launch on Tuesday, writes Marijuana Moment.
- CBD Market
Illinois hits a record $1.5 billion of cannabis sales in 2022
SALES RECORD Illinois hits a record $1.5 billion of cannabis sales in 2022 Illinois cannabis sales reached a record high of more than $1.5 billion in 2022, with December marking the strongest sales month to date, writes Marijuana Moment.
- Pharmaceutical
European Cannabis Stocks Review: Akanda Reports $2.3m Loss From Bophelo, OCT Shares Spike & Cellular Goods Sales Slow
Akanda Akanda unveiled its unaudited financial figures for the six months to the end of June 2022, two weeks after revealing that its CEO has been on ‘paid leave of absence’ since November.
